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As our ongoing work on research of anti-HIV-1 inhibitors, fifteen N-arylsulfonyl-3-formylindoles (3a-
o) were designed and prepared through two step synthetic route. Firstly, 3-formylindoles (2a-c) were 
synthesized via the Vilsmeier-Haack reaction. Subsequently, treatment of 2a-c with the appropriate 
arylsulfonyl chlorides led to the corresponding target compounds in excellent yields. All analogues were 
also preliminary evaluated in vitro for their inhibitory activity against HIV-1 replication. Among of all 
the reported analogues, three compounds 3c, 3g and 3i displayed significant anti-HIV-1 activity, with 
EC50 values of 9.57, 11.04 and 5.02 μM, and TI values of 31.89, 13.79 and 81.69, respectively. N-m-
nitrophenylsulfonyl-3-formylindole (3c) and N-m-nitrophenylsulfonyl-6-methyl-3-formylindole (3i) 
especially exhibited the best promising anti-HIV-1 activity. In addition, it demonstrated that insertion 
of a methyl group at the C-6 position of the indolyl ring and a nitro group at the meta position of the 
arylsulfonyl ring, as in compound 3i, resulted in both low cytotoxicity (CC50 = 410.41 μM) and good 
antiviral activity.
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INTRODUCTION
Acquired immune deficiency syndrome (AIDS) is 
usually caused by human immunodeficiency virus type 1 
(HIV-1) infection and pandemic continues to be a global 
problem for public health (Faria et al., 2014; Piot, Quinn, 
2013; Sampériz et al., 2014). According to Joint United 
Nations Programme on AIDS (UNAIDS)-2015 report, 
it is estimated that, approximately 36.9 million people 
(2.6 million of them were children) were living with HIV 
infection, and 1.2 millions died due to the infected with 
HIV and related diseases in the year 2014 (Chander et al., 
2016; Global HIV and AIDS Statistics, 2015). 
The reverse transcriptase (RT) of the HIV-1 plays a 
pivotal role in the viral replication process, which makes 
it a crucial target for anti-HIV-1 inhibitors research 
(Jonckheere, Anné, De Clercq, 2000; Yisma et al., 
2014). In spite of numerous RT inhibitors (including the 
nucleotide RT inhibitors (NRTIs) and non-nucleotide RT 
inhibitors (NNRTIs) have been discovered and developed, 
like other anti-HIV-1 inhibitors, effectiveness of currently 
approved NRTIs and NNRTIs have been hampered 
because of their severe side effects and the aggravation of 
viral variants resistant to HIV-1 drug (Boone, 2006; De 
Clercq, 2002; Sluis-Cremer, Wainberg, Schinazi, 2015; 
Yu et al., 2011). To circumvent this challenge, there is an 
urgent require to develop new, efficacy, selective and safe 
HIV-1 inhibitors having significant potency against drug-
resistant RT viral strains and less toxicity still remains a 
high priority for medical research (Huang et al., 2007; 
Polanski et al., 2006; Safakish et al., 2017).
To the best of our knowledge, N-arylsulfonylindoles 
or N-arylsulfonyl-3-acylindoles are excellent candidates 
for the study of serotonin 5-HT6 receptor (Pullagurla et al., 
2005; Russell et al., 2001; Tsai et al., 2000) or anti-HIV-1 
inhibitors (Che et al., 2016; Fan et al., 2009; Ran et al., 
2010), and especially some N-arylsulfonyl-3-acetylindoles 
showed potent anti-HIV-1 activity. The general structural 
formula of N-arylsulfonylindoles and N-arylsulfonyl-
3-acylindoles (Figure 1) is shown as a formula I-III. 
Nevertheless, no attention has been paid to the anti-HIV-1 
activity of the N-arylsulfonyl-3-formylindoles. Inspired by 
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these previous observations, and the aim in our program 
is to discover and develop novel compounds with potent 
biological activity (Che et al., 2013a; Che et al., 2015; 
Che et al., 2013b), we report here the results of the 
synthesis and anti-HIV-1 activity of 15 N-arylsulfonyl-3-
formylindole derivatives. Furthermore, an investigation 
of preliminary structure activity relationship (SAR) was 
also discussed in detail.
RESULTS AND DISCUSSION
Chemistry
N-arylsulfonyl-3-formylindoles 3a-o (Figure 2) 
were prepared using two step synthetic route, reaction 
conditions used for the synthesis of fifteen target 
compounds are outlined in Scheme 1. Firstly, treatment 
of commercially available indoles (1a-c) with N, 
N-dimethylformamide (DMF) solution in phosphorus 
oxychloride (POCl3) provided an iminium intermediate, 
which followed by basic hydrolysis with 30% aqueous 
sodium hydroxide (NaOH) afforded 3-formylindoles 
(2a-c) (Ge, Wu, Xue, 2006). Secondly, introduction of 
the arylsulfonyl moieties were performed by reacting 
2a-c with the appropriate arylsulfonyl chlorides in the 
presence of potassium carbonate (K2CO3) to produce the 
corresponding target compounds (3a-o) in excellent yields 
(Abid, Teixeira, Torok, 2007). Compounds 2a-c, 3a-e, 
3g-j, 3l and 3n were known compounds and characterized 
by comparison of the data as described in our previous 
paper (Che et al., 2013b).
Biological activities
Purified and characterized 3-formylindoles (2a-c) 
and N-arylsulfonyl-3-formylindoles (3a-o) were screened 
in vitro for their inhibitory activity against HIV-1 
replication in acutely infected C8166 cells, and 3′-azido-
FIGURE 1 - Chemical structure of N-arylsulfonylindoles (I), N-arylsulfonyl-3-acetylindoles (II) and N-arylsulfonyl-3-
propionylindoles (III).
FIGURE 2 - Chemical structures of N-arylsulfonyl-3-formylindoles 3a-o.
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3′-deoxythymidine (AZT) was used as a positive control 
(see Table I). The results of anti-HIV-1 activity detection 
revealed that, out of 15 screened N-arylsulfonyl-3-
formylindoles, one (3i) displayed the most significant 
(effective concentration causing 50% inhibition of 
syncytia formation (EC50) values of 5.02 μM, therapeutic 
index (TI) values of 81.69), two (3c and 3g) showed 
moderate (EC50 values of 9.57 and 11.04 μM, TI values 
of 31.89 and 13.79, respectively), while the rest of tested 
compounds exhibited relatively weak HIV-1 inhibitory 
activity (EC50 values of 11.70 to 46.67 µM, except 3e, the 
EC50 values of 7.90 μM, and TI values of 0.59 to 9.89).
Consequently, based upon the above investigation, 
when the arylsulfonyl moieties were introduced on the 
1-position of the indole′s ring, the anti-HIV-1 activity of 
the corresponding compounds were significantly increased 
(2a vs 3a-f; 2b vs 3g-k; 2c vs 3l-o). For example, the EC50 
value of 2a (EC50 = 454.19 μM) was close to 21 times of 
that of 3c (EC50 = 9.57 μM), the TI value of 3c (TI = 31.89) 
was more than 16 times of that of 2a (TI = 1.96); the EC50 
value of 2b (EC50 = 428.50 μM) was more than 39 times of 
that of 3i (EC50 = 5.02 μM), the TI value of 3i (TI = 81.69) 
was close to 134 times of that of 2b (TI = 0.61); the EC50 
value of 2c (EC50 = 480.35 μM) was more than 6 times of 
that of 3n (EC50 = 37.63 μM), the TI value of 3n (TI = 8.94) 
was more than 9 times of that of 2c (TI = 0.97).
In order to elucidate the HIV-1 inhibitory activity of 
3a-o on a molecular level as well as to disclose structural 
features critical for their activity, an investigation of 
preliminary structure activity relationship (SAR) was 
determined in detail, which revealed that the electronic 
effect of various substituted on N-arylsulfonyl-3-
formylindoles were related to HIV-1 inhibitory activity. 
In general, (1) Introducing an electron-withdrawing group 
(such as a nitro group) on the arylsulfonyl ring, could result 
in the more potent compound than the corresponding one 
having an electron-donating group (such as a methyl or 
methoxyl group) (3c vs 3a and 3b; 3i vs 3g and 3h; 3n vs 
3l and 3m). For example, the EC50 and TI values of 3c, 3a 
and 3b were 9.57, 13.66, 11.70 μM, and 31.89, 7.18, 3.72, 
respectively; that is, the TI value of 3c was more than 8 
times of that of 3b and was more than 4 times of that of 3a. 
The EC50 and TI values of 3i, 3g and 3h were 5.02, 11.04, 
41.99 μM, and 81.69, 13.79, 4.68, respectively; that is, the 
TABLE I - Anti-HIV-1 activity of n-arylsulfonyl-3-formylindoles 
3a-o in vitroa
Compounds CC50b(μM) EC50c(μM) TId
2a 889.79 454.19 1.96
3a 98.15 13.66 7.18
3b 43.48 11.70 3.72
3c 305.04 9.57 31.89
3d 308.04 31.15 9.89
3e 12.12 7.90 1.53
3f 80.67 11.23 7.18
2b 260.89 428.50 0.61
3g 152.22 11.04 13.79
3h 196.62 41.99 4.68
3i 410.41 5.02 81.69
3j 77.02 11.62 6.63
3k 13.31 9.13 1.46
2c 465.54 480.35 0.97
3l 194.51 39.93 4.87
3m 151.37 32.88 4.60
3n 336.51 37.63 8.94
3o 27.40 46.67 0.59
AZTe 4263.82 0.01212 351688.27
aValues are means of two separate experiments (the values 
exhibited standard deviation (SD) less than ±5% from mean). 
bCC50 (50% cytotoxic concentration), concentration of drug that 
causes 50% reduction in total C8166 cell number. cEC50 (50% 
effective concentration), concentration of drug that reduces 
syncytia formation by 50%. dIn vitro therapeutic index (CC50 
value / EC50 value). eAZT was used as a positive control.
SCHEME 1 - Synthetic route for the preparation of 3-formylindoles (2a-c) and N-arylsulfonyl-3-formylindoles 3a-o.
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TI value of 3i was more than 17 times of that of 3h and 
was close to 6 times of that of 3g. The EC50 and TI values 
of 3n, 3l and 3m were 37.63, 39.93, 32.88 μM, and 8.94, 
4.87, 4.60, respectively; that is, the TI value of 3n was 
nearly 2 times of that of 3m and was close to 2 times of 
that of 3l. (2) Interestingly, variations at the C-4 position 
of the arylsulfonyl ring outbalance to anti-HIV-1 activities 
for the corresponding compounds (3a vs 3b; 3g vs 3h; 
3l vs 3m; 3d vs 3f). For example, 4-methyl was more 
significant for the anti-HIV-1 activities than 4-ethyl; 
4-chloro was more essential for the anti-HIV-1 activities 
than 4-bromo. The EC50 and TI values of 3a, 3b, 3g, 3h, 
3l, 3m, 3d and 3f were 13.66, 11.70, 11.04, 41.99, 39.93, 
32.88, 31.15 and 11.23 μM, and 7.18, 3.72, 13.79, 4.68, 
4.87, 4.60, 9.89 and 7.18, respectively. (3) In contrast, 
when two electron-withdrawing groups (such as nitro and 
chloro groups) were introduced on the arylsulfonyl ring, 
the anti-HIV-1 activities of the corresponding compounds 
were decreased sharply as compared with those containing 
one electron-withdrawing group (3e vs 3c and 3d; 3k vs 3i 
and 3j; 3o vs 3n). For example, the EC50 and TI values of 
3e, 3k and 3o were 7.90, 9.13, 46.67 μM, and 1.53, 1.46, 
0.59, respectively; that is, the TI value of 3c was more than 
20 times of that of 3e; the TI value of 3d was more than 6 
times of that of 3e; the TI value of 3i was close to 56 times 
of that of 3k; the TI value of 3j was more than 4 times of 
that of 3k; the TI value of 3n was more than 15 times of 
that of 3o. (4) When a methyl group was introduced at the 
C-6 position of the indolyl ring, the anti-HIV-1activities 
of the corresponding compounds were more pronounced 
than those of the compounds carrying a hydrogen group 
or a cyano group (TI = 13.79 for 3g vs TI = 7.18 for 3a and 
TI = 4.87 for 3l; TI = 4.68 for 3h vs TI = 3.72 for 3b and 
TI = 4.60 for 3m; TI = 81.69 for 3i vs TI = 31.89 for 3c 
and TI = 8.94 for 3n). (5) In the meantime, it is noteworthy 
that insertion of a methyl group at the C-6 position of the 
indolyl ring and a nitro group at the meta position of the 
arylsulfonyl ring, as in compound 3i, resulted in both 
low cytotoxicity (cytotoxic concentration causing 50% 
reduction in total C8166 cell number (CC50) = 410.41 μM) 
and high antiviral activity (TI = 81.69).
It is noteworthy that introduction of the formyl group 
at the 3-position of N-arylsulfonylindoles could generally 
lead to the more potent compounds (e.g., 3c, 3g and 3i) 
relative to those containing 1,3-thiazolidin-4-ones group 
(e.g., 4, 5 and 6, Figure 3). The EC50 and TI values of three 
compounds of containing 1,3-thiazolidin-4-ones group 
at the 3-position of N-arylsulfonylindoles were 172.04, 
93.46, 47.21 μM, and >2.36, >4.20, >8.58, respectively; 
that is, the EC50 value of 4 was close to 27 times of that 
of 3c, the EC50 value of 5 was close to 14 times of that of 
3g, the EC50 value of 6 was more than 13 times of that 
of 3i (Yang et al., 2012). Therefore, further chemical 
modifications should be deliberately manipulated so as to 
exploit more potent inhibitors.
EXPERIMENTAL SECTION
General information
Unless specified otherwise, all solvents and reagents 
were commercially available or purified by standard 
techniques before use. All reactions were monitored by 
thin-layer chromatography (TLC) on silica gel plates 
using silica gel 60 GF254 (Qingdao Haiyang Chemical 
Co., Ltd.). Yields were recorded by purification, and 
preparative thin-layer chromatography (PTLC) was 
performed with silica gel plates. Melting points were 
determined using digital melting-point apparatus (Beijing 
Tech Instrument Co., Ltd.). Nuclear magnetic resonance 
spectra (NMR) were recorded on a Bruker Avance 
DMX 500 MHz instrument (Bruker Daltonik, Bremen, 
Germany) in CDCl3 or DMSO-d6 (1H at 500 MHz and 
13C at 125 MHz) using tetramethylsilane (TMS) as the 
internal standard. Electrospray iontrap mass spectrometry 
(ESI-TRAP-MSn) was performed on a Bruker ESI-TRAP 
Esquire 3000 plus mass spectrometry instrument (Bruker 
Daltonics, San Diego, California, USA). The purities of 
FIGURE 3 - Chemical structure of 2-(N-m-nitrophenylsulfonylindol-3-yl)-3-p-methylphenyl-1,3-thiazolidin-4-ones (4), 2-(N-p-
methylphenylsulfonyl-6-methylindol-3-yl)-3-p-nitrophenyl-1,3-thiazolidin-4-ones (5) and 2-(N-m-nitrophenylsulfonyl-6-
methylindol-3-yl)-3-phenyl-1,3-thiazolidin-4-ones (6).
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the target compounds were determined by reverse phase 
high-performanceliquid chromatography (RP-HPLC) 
recorded on a Shimadzu LC-15C liquid chromatograph 
[SPD-15C UV-Vis spectrophotometric detector (190-700 
nm); Shimadzu, Kyoto, Japan] using a Hypersil ODS C18 
column (5 μm, 4.6 × 150 mm) as the stationary phase.
Preparation of N-arylsulfonyl-3-formylindoles 
(3a-o)
A mixture of DMF (5 mL) and POCl3 (0.5 mL) was 
stirred at 0 °C for 10 min. A solution of indoles (1a-c, 5 
mmol) in 2 mL DMF was added dropwise to the former 
mixture. After the addition, the mixture was stirred at 35 
°C for 1 h, then 100 mL water was added, followed by the 
addition of 30% aqueous NaOH to adjust the pH value 
to 8-9. The mixture was refluxed for 1 h. On cooling, the 
solution was poured into ice water, and the precipitated 
product was collected, washed by water, and then washed 
with a certain amount of petroleum ether until it was pure, 
monitored by TLC. The pure compounds were dried in 
vacuum drying chamber to afford 3-formylindoles 2a-c 
in excellent yields. Subsequently, a solution of 2a-c 
(1 mmol), substituted arylsulfonyl chlorides (2 mmol), and 
K2CO3 (3 mmol) in dry acetone/dichloromethane (10 mL) 
was refluxed for 12-20 h, till the completion of the reaction 
as monitored by TLC. The reaction mixture was filtered, 
and the filtrate was merged, the crude product was purified 
by PTLC (petroleum ether/ethyl acetate, 1/1) to obtain 
pure compounds 3a-o in 63-99% yields, and its purity was 
>95% as measured with RP-HPLC. The typical spectral 
data of compounds 3f, 3k, 3m and 3o were as follows.
N-p-Bromophenylsulfonyl-3-formylindole (Weng 
et al., 2007) 3f: Tan solid, Yield = 63%, m.p. 145-147 oC. 
1H NMR (500 MHz, CDCl3) δ: 10.10 (s, 1H), 8.27 (d, 
J = 7.5 Hz, 1H), 8.19 (s, 1H), 7.93 (d, J = 8.5 Hz, 1H), 
7.80-7.82 (m, 2H), 7.63-7.65 (m, 2H), 7.37-7.44 (m, 2H). 
MS (ESI-TRAP-MSn), m/z (%): 364 ([M+H]+, 100).
N-m-Nitro-p-chlorophenylsulfonyl-6-methyl-
3-formylindole 3k: Yellow solid, Yield = 73%, m.p. 
153-155 oC. 1H NMR (500 MHz, CDCl3) δ: 10.08 (s, 1H), 
8.48 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.11 
(s, 1H), 8.02-8.04 (m, 1H), 7.71-7.73 (m, 2H), 7.25 (dd, 
J = 8.0 Hz, 0.5 Hz, 1H), 2.52 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ: 186.4, 148.1, 137.5, 136.1, 135.7, 133.0, 131.6, 
130.7, 128.3, 125.5, 124.3, 122.7, 119.2, 113.2, 21.5. MS 
(ESI-TRAP-MSn), m/z (%): 377 ([M–H]–, 100).
N - p - M e t h o x y l p h e n y l s u l f o n y l - 5 - c y a n o -
3-formylindole 3m :  White sol id,  Yield = 88%, 
m.p. 238-240 oC. 1H NMR (500 MHz, DMSO-d6) δ: 10.09 
(s, 1H), 9.06 (s, 1H), 8.50 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H), 
8.13 (d, J = 9.0 Hz, 2H), 7.89 (dd, J = 9.0 Hz, 1.5 Hz, 1H), 
7.18 (d, J = 9.0 Hz, 2H), 3.83 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ: 199.1, 186.1, 147.5, 139.3, 135.2, 132.1, 
130.4, 129.0, 127.5, 125.4, 120.7, 118.3, 114.7, 107.4, 
56.3. MS (ESI-TRAP-MSn), m/z (%): 339 ([M–H]–, 100).
N-m-Nitro-p-chlorophenylsulfonyl-5-cyano-
3-formylindole 3o :  Yellow solid,  Yield = 76%, 
m.p. 228-230 oC. 1H NMR (500 MHz, DMSO-d6) δ: 10.10 
(s, 1H), 9.09 (s, 1H), 8.92 (d, J = 2.0 Hz, 1H), 8.48-8.50 
(m, 2H), 8.24 (d, J = 9.0 Hz, 1H), 8.09 (d, J = 9.0 Hz, 1H), 
7.91 (dd, J = 8.5 Hz, 1.5 Hz, 1H). 13C NMR (125 MHz, 
DMSO-d6) δ: 199.1, 186.2, 148.0, 140.1, 136.1, 132.5, 
130.3, 129.7, 127.9, 125.4, 119.9, 118.8, 115.1, 107.7. MS 
(ESI-TRAP-MSn), m/z (%): 388 ([M–H]–, 100).
Anti-HIV-1 activity assay
Cells and virus
Cell line (C8166) and the laboratory-derived virus 
(HIV-1IIIB) were obtained from MRC, AIDS Reagent 
Project, UK. C8166 was maintainedin RPMI-1640 
supplemented with 10% heat-inactivated newborn calf 
serum (Gibco). The cells used in all experiments were 
in log-phasegrowth. The 50% HIV-1IIIB tissue culture 
infectious dose (TCID50) in C8166 cells was determined 
and calculated by the Reed and Muench method. Virus 
stocks were stored in small aliquots at -70 oC.
MTT-based cytotoxicity assay
Cellular toxicity of 3-formylindoles (2a-c) and 
N-arylsulfonyl-3-formylindoles (3a-o) on C8166 cells 
was assessed by MTT method as described previously. 
Briefly, cells were seeded on 96-well microtiter plate 
in the absence or presence of various concentrations of 
N-arylsulfonyl-3-formylindoles in triplicate and incubated 
at 37 oC in a humid atmosphere of 5% CO2 for 3 d. The 
supernatants were discarded and MTT reagent (5 mg/mL 
in PBS) was added to each wells, then incubated for 4 h, 
100 μL of 50% N, N-dimethylformamide (DMF)-20% SDS 
was added. After the formazan was dissolved completely, 
the plates were read on a Bio-TekElx800 ELISA reader 
at 595/630 nm. The cytotoxic concentration that caused 
the reduction of viable C8166 cells by 50% (CC50) was 
determined from dose-response curve.
Syncytia assay
In the presence of 100 μL various concentrations of 
N-arylsulfonyl-3-formylindoles, C8166 cells (4 × 105/mL) 
were infected with virus HIV-1IIIB at a multiplicity of 
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infection (M.O.I) of 0.06. The final volume per well was 
200 μL. Control assays were performed without the testing 
compounds in HIV-1IIIB infected and uninfected cultures. 
After 3 d of culture, the cytopathic effect (CPE) was 
measured by counting the number of syncytia. Percentage 
inhibition of syncytia formation was calculated and 
50% effective concentration (EC50) was calculated. AZT 
(Sigma) was used as a positive control. Therapeutic index 
(TI) = CC50/EC50.
CONCLUSIONS
In  conc lus ion ,  f i f t een  N -a ry l su l fony l -3 -
formylindoles (3a-o) were prepared and preliminarily 
evaluated as HIV-1 inhibitors in vitro. Especially, 
N-m-nitrophenylsulfonyl-3-formylindole (3c) and 
N-m-nitrophenylsulfonyl-6-methyl-3-formylindole 
(3i) displayed moderate anti-HIV-1 activity with EC50 
values of 9.57 and 5.02 μM, and TI values of 31.89 and 
81.69, respectively. In addition, it demonstrated that 
introduction of the methyl group at the C-6 position of 
the indolyl ring and the nitro group at the meta position 
of the phenylsulfonyl ring were two certainly important 
functional groups for 3i being significant anti-HIV-1 
activity.
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